Carnegie Investment Counsel’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-102,112
| Closed | -$5.52M | – | 468 |
|
|
2024
Q2 | $5.52M | Buy |
102,112
+34,500
| +51% | +$1.86M | 0.17% | 131 |
|
|
2024
Q1 | $4.61M | Sell |
67,612
-5,925
| -8% | -$404K | 0.14% | 147 |
|
|
2023
Q4 | $4.6M | Sell |
73,537
-15,180
| -17% | -$950K | 0.16% | 143 |
|
|
2023
Q3 | $4.03M | Buy |
88,717
+27,875
| +46% | +$1.27M | 0.15% | 145 |
|
|
2023
Q2 | $3.42M | Buy |
+60,842
| New | +$3.42M | 0.13% | 157 |
|
|
2023
Q1 | – | Sell |
-25,682
| Closed | -$1.04M | – | 509 |
|
|
2022
Q4 | $1.04M | Sell |
25,682
-32,700
| -56% | -$1.33M | 0.04% | 274 |
|
|
2022
Q3 | $3.82M | Sell |
58,382
-28,770
| -33% | -$1.88M | 0.18% | 133 |
|
|
2022
Q2 | $5.3M | Buy |
87,152
+989
| +1% | +$60.1K | 0.24% | 112 |
|
|
2022
Q1 | $5.41M | Sell |
86,163
-32,189
| -27% | -$2.02M | 0.2% | 128 |
|
|
2021
Q4 | $8.97M | Sell |
118,352
-575
| -0.5% | -$43.6K | 0.3% | 99 |
|
|
2021
Q3 | $13.3M | Buy |
118,927
+1,755
| +1% | +$196K | 0.5% | 67 |
|
|
2021
Q2 | $19M | Buy |
117,172
+7,691
| +7% | +$1.25M | 0.72% | 48 |
|
|
2021
Q1 | $13.3M | Buy |
109,481
+15,289
| +16% | +$1.86M | 0.56% | 57 |
|
|
2020
Q4 | $14.4M | Buy |
94,192
+4,927
| +6% | +$754K | 0.65% | 52 |
|
|
2020
Q3 | $7.47M | Sell |
89,265
-2,455
| -3% | -$205K | 0.38% | 84 |
|
|
2020
Q2 | $6.74M | Buy |
91,720
+25,460
| +38% | +$1.87M | 0.39% | 79 |
|
|
2020
Q1 | $2.81M | Buy |
66,260
+28,650
| +76% | +$1.22M | 0.2% | 124 |
|
|
2019
Q4 | $2.29M | Buy |
37,610
+12,440
| +49% | +$758K | 0.13% | 155 |
|
|
2019
Q3 | $1.03M | Buy |
25,170
+2,570
| +11% | +$105K | 0.07% | 216 |
|
|
2019
Q2 | $1.06M | Buy |
+22,600
| New | +$1.06M | 0.07% | 210 |
|